Introduction
============

According to the Cancer Statistics of 2019, prostate cancer (PCa) has emerged as the second most frequently diagnosed malignancy and is estimated to be the second leading cause of cancer-related mortalities among American males ([@ref-56]). At present, prostate specific antigen (PSA) has been the most routinely used biomarker for the screening and monitoring of PCa ([@ref-22]). However, elevated PSA does not necessarily indicate PCa and often leads to false positive results as well as overdiagnosis since it can also be seen in other benign lesions such as prostatitis or benign prostatic hyperplasia ([@ref-26]; [@ref-33]). Therefore, excavating reliable and effective biomarkers and learning hub genes involved in the biological process (BP) of PCa is urgently needed.

With the development of high-throughput sequencing technology and bioinformatic analysis methods, the gene expression omnibus (GEO) online public database has been widely utilized to screen out differentially expressed genes (DEGs), to study molecular signals and their relations, and to aid in constructing gene regulatory networks ([@ref-12]). Up to now, by either analysis of a single dataset or integrated analysis of multiple datasets in GEO, several studies have dug out genes that exert important influence on the occurrence and progression of PCa, such as cadherin 1 (CDH1) ([@ref-19]), CDCA8 ([@ref-71]), RPS21 ([@ref-18]), PIK3R1 ([@ref-24]), epithelial cell adhesion molecule (EPCAM) ([@ref-36]), LMNB1 ([@ref-57]), IGF2 ([@ref-61]), and IKZF1 ([@ref-64]). However, the key genes detected by the above studies are largely different from each other and had little in common, and such discrepancy could be attributed to the fact that PCa is considered as a heterogenous disease as a whole ([@ref-32]; [@ref-63]). As a consequence, further studies in this regard is still required for the exploration and validation of key genes.

In [@ref-8] studied the immune microenvironment in four solid cancer types including PCa and uploaded the corresponding gene expression profile dataset [GSE103512](GSE103512). For the first time, the present study employed the [GSE103512](GSE103512) dataset to screen out the DEGs between 60 PCa and seven matched normal prostate (NP) tissue, and a total of 252 DEGs were detected. The gene ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the DEGs were performed, following by the construction of the protein--protein interaction (PPI) network which could uncover the underlying molecular mechanisms involved in the development of PCa. The cytoHubba and MCODE plugins of the Cytoscape software was applied to identify the hub genes and functional modules in the constructed PPI network, respectively. The Cancer Genome Atlas (TCGA) database, the Oncomine database, and the results reported by former studies were utilized for validation of our outcomes.

Materials and Methods
=====================

Microarray data
---------------

The [GSE103512](GSE103512) gene expression profile CEL files, which consisted of 60 PCa samples of different TNM staging and Gleason grading and seven matched NP samples ([@ref-8]), were downloaded from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). The gene probe IDs in the CEL files were converted to their corresponding gene symbols based on the annotation information of the platform GPL13158 (Affymetrix HT HG-U133+ PM Array Plate), which contains 54,715 probes.

Data processing and screening of DEGs
-------------------------------------

The CEL files of [GSE103512](GSE103512) were read using the affy package of the R programing language (Ver. 3.6.0). Data preconditioning (including background adjustment, normalization, and summarization) were performed using the Robust Multi-array Average method. The limma package of R was adopted to identify the DEGs between PCa and NP samples, with a \|log~2~ fold change\| ≥ 1 and a *P* \< 0.05 was deemed to be of statistically significance ([@ref-52]). The overall upregulated and downregulated DEGs information were saved for further analyses.

Functional and enrichment analyses of DEGs
------------------------------------------

The present study adopted the Database for Annotation Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>) to obtain GO annotation and KEGG pathway enrichment information of the DEGs identified previously ([@ref-15]). Results with *P* \< 0.05 with count number ≥2 were regarded as statistically significant.

PPI network construction and modules analyses
---------------------------------------------

Protein--protein interaction analysis serves as an entry point for better interpretation of relationships between different proteins on a genome-wide scale, and might be helpful to provide novel insights into protein function explanation ([@ref-59]). PPI relationships of DEGs was analyzed and the corresponding PPI network was constructed by the Search Tool for the Retrieval of Interacting Genes (STRING) database online tool (<http://string-db.org/>) ([@ref-65]). All DEGs were subsequently submitted to the Cytoscape software for network visualization and hub gene identification, which was realized by the cytoHubba plugin. In addition, the MCODE plugin of Cytoscape was applied to identify potential functional modules in the PPI network with default parameters (degree cutoff ≥ 2, node score cutoff ≥ 2, *K*-core ≥ 2, and max depth = 100) ([@ref-4]).

Validation of hub genes
-----------------------

First, we performed a literature search regarding gene expression profiles of PCa in Pubmed and then extracted hub genes reported by the eligible studies, which was used to compare with those identified in the present study. Next, we examined the relative mRNA expression levels of the identified hub genes using the Gene Expression Profiling Interactive Analysis (GEPIA) and Oncomine online tools for further validation. The GEPIA (<http://gepia.cancer-pku.cn/>) provides comprehensive online services based on TCGA database, and we used the differential expression analysis and patient survival analysis functions in this case ([@ref-62]). The Oncomine online database (<https://www.oncomine.org/>) was applied to examine the mRNA expression of hub genes in both multiple cancers and their corresponding normal tissues ([@ref-51]).

Survival analysis of hub genes
------------------------------

Provided by the University of California Santa Cruz (UCSC), the UCSC Xena online tools (<https://xenabrowser.net>) enables researchers to study functional genomic datasets for correlations between genomic and/or phenotypic variables. In this case we used this tool to study whether the expression of hub genes was correlated with the survival of PCa patients from TCGA cohorts. Patients were categorized into a relatively high and low expression group respectively based on the median expression value of genes, and their overall survivals (OSs) were analyzed using the Kaplan--Meier method with a log-tank test. A *P* \< 0.05 was deemed as statistically significant.

Results
=======

Data processing and screening of DEGs
-------------------------------------

The PCa microarray expression dataset [GSE103512](GSE103512) contained information of mRNA expression of 60 PC samples and seven matched NP samples. A total of 19,918 official gene symbols were discerned and the gene expression matrix was constructed. The DEGs were filtered using the limma R package (criteria: adjusted *P* \< 0.05 and \|log~2~ fold change\| ≥ 1). A total of 252 DEGs were identified between PCa and NP samples, including 186 upregulated genes and 66 downregulated genes. The top 10 upregulated and downregulated DEGs based on fold changes are listed in [Table 1](#table-1){ref-type="table"}. The volcano plot of all the genes detected and the cluster heatmap of the 252 DEGs were collected in [Fig. 1](#fig-1){ref-type="fig"}.

![The volcano plot and heatmap of the DEGs.\
(A) Volcano plot: The abscissa represents log~2~FC and the ordinate represents −log~10~(adjusted *P*-value). The blue, purple, gray, red, and yellow dots represent significantly upregulated DEGs, significantly downregulated DEGs, insignificant DEGs, top 10 up/downregulated DEGs, and hub genes between PCa and NP tissues, respectively. (B) Cluster heatmap of the DEGs. DEG, differentially expressed gene; FC, fold change; PCa, prostate cancer; NP, normal prostate.](peerj-07-7872-g001){#fig-1}
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###### Top 10 upregulated and downregulated DEGs between PCa and NP tissues.

![](peerj-07-7872-g007)

  Gene symbol    Log~2~FC       adj.P.Val     State
  -------------- -------------- ------------- ---------------
  NPY            −3.362711603   0.000789175   Upregulated
  TARP           −3.206862002   4.85E-09      Upregulated
  OR51E2         −2.828448822   7.28E-05      Upregulated
  NKX3-1         −2.528690546   3.58E-12      Upregulated
  MSMB           −2.517978536   5.11E-06      Upregulated
  ACPP           −2.474802744   2.29E-09      Upregulated
  SLC45A3        −2.46284327    2.66E-08      Upregulated
  C15orf21       −2.327851135   0.003615423   Upregulated
  ABCC4          −2.261776258   1.46E-08      Upregulated
  LOC100287445   −2.170028348   0.000544702   Upregulated
  FOLR1          3.005860886    8.83E-09      Downregulated
  KRT13          2.958317838    2.03E-08      Downregulated
  SEMG1          2.881097184    0.001633121   Downregulated
  SEMG2          2.444264593    0.00246384    Downregulated
  OLFM4          2.410939695    0.000494142   Downregulated
  SLPI           2.391184301    3.98E-05      Downregulated
  SCGB1A1        2.324648206    2.40E-05      Downregulated
  OSR1           2.028908547    3.00E-15      Downregulated
  HSPB6          1.791949206    1.19E-06      Downregulated
  CFD            1.71042558     1.42E-09      Downregulated

**Note:**

DEG, differentially expressed gene; PCa, prostate cancer; NP, normal prostate; FC, fold change; adj.P.Val, adjusted *P*-value.

Functional and pathway enrichment analyses of DEGs
--------------------------------------------------

Gene ontology function annotation of the identified DEGs was obtained using the DAVID database and its online analysis tool, which included the following three portions: BP, cell component (CC), and molecular function (MF). The results were deemed as statistically significant if *P* \< 0.05, and the top 15 GO terms of the upregulated and downregulated DEGs are compiled in [Table 2](#table-2){ref-type="table"}. As shown in [Fig. 2A](#fig-2){ref-type="fig"}, the upregulated genes were mainly enriched in oxidation-reduction process (ontology: BP), extracellular exosome (ontology: CC), and calcium ion binding (ontology: MF). As shown in [Fig. 2B](#fig-2){ref-type="fig"}, the downregulated genes were mainly enriched in positive regulation of transcription from RNA polymerase II promoter (ontology: BP), extracellular exosome (ontology: CC), and protein binding (ontology: MF).

![The GO/KEGG enrichment analyses of the DEGs.\
(A) Top 15 enriched GO terms of the upregulated DEGs. (B) Top 15 enriched GO terms of the downregulated DEGs. (C) Top five enriched pathways of the upregulated DEGs. (D) Top five enriched pathways of the downregulated DEGs. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cell component; MF, molecular function.](peerj-07-7872-g002){#fig-2}
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###### Top 15 enriched gene ontology terms of the upregulated and downregulated DEGs.

![](peerj-07-7872-g008)

  Category   Term                                                                   Count   *P*-value     State
  ---------- ---------------------------------------------------------------------- ------- ------------- ---------------
  BP         Oxidation-reduction process                                            17      1.10E-04      Upregulated
  BP         Proteolysis                                                            11      0.01703296    Upregulated
  BP         Long-chain fatty-acyl-CoA biosynthetic process                         6       3.93E-05      Upregulated
  BP         Response to organic cyclic compound                                    4       0.01023923    Upregulated
  BP         Response to endoplasmic reticulum stress                               4       0.031611372   Upregulated
  CC         Extracellular exosome                                                  74      2.91E-19      Upregulated
  CC         Integral component of membrane                                         65      0.001627446   Upregulated
  CC         Plasma membrane                                                        56      7.29E-04      Upregulated
  CC         Membrane                                                               34      0.00188457    Upregulated
  CC         Extracellular space                                                    27      1.58E-04      Upregulated
  MF         Calcium ion binding                                                    13      0.032748281   Upregulated
  MF         Oxidoreductase activity                                                9       5.26E-04      Upregulated
  MF         Actin binding                                                          9       0.004195153   Upregulated
  MF         Serine-type peptidase activity                                         7       2.40E-05      Upregulated
  MF         Serine-type endopeptidase activity                                     7       0.030442507   Upregulated
  BP         Positive regulation of transcription from RNA polymerase II promoter   8       0.047270726   Downregulated
  BP         Negative regulation of transcription from RNA polymerase II promoter   7       0.034624047   Downregulated
  BP         Negative regulation of cell growth                                     4       0.008047189   Downregulated
  BP         Extracellular matrix organization                                      4       0.028910713   Downregulated
  BP         Collagen fibril organization                                           3       0.007739592   Downregulated
  CC         Extracellular exosome                                                  23      3.41E-05      Downregulated
  CC         Extracellular space                                                    20      2.27E-08      Downregulated
  CC         Extracellular region                                                   15      4.96E-04      Downregulated
  CC         Extracellular matrix                                                   6       0.002673098   Downregulated
  CC         Blood microparticle                                                    4       0.013152355   Downregulated
  MF         Protein binding                                                        34      0.021626321   Downregulated
  MF         Drug binding                                                           4       0.001392245   Downregulated
  MF         Protein dimerization activity                                          4       0.009398722   Downregulated
  MF         ATPase activity                                                        4       0.016027571   Downregulated
  MF         Sodium:potassium-exchanging ATPase activity                            2       0.028658029   Downregulated

**Note:**

BP, biological process; CC, cell component; MF, molecular function.

The ensuing KEGG pathway analyses were also performed using the online analysis tool of DAVID database and the results were collected in [Table 3](#table-3){ref-type="table"}. As shown in [Fig. 2C](#fig-2){ref-type="fig"}, the upregulated DEGs enriched in five pathways: (1) metabolic pathways, (2) fatty acid (FA) metabolism, (3) arginine and proline metabolism, (4) Peroxisome-activated receptor (PPAR) signaling pathway, and (5) FA biosynthesis. As shown in [Fig. 2D](#fig-2){ref-type="fig"}, the downregulated DEGs enriched in five pathways: (1) protein digestion and absorption, (2) aldosterone-regulated sodium reabsorption, (3) carbohydrate digestion and absorption, (4) mineral absorption, and (5) endocrine and other factor-regulated calcium reabsorption. The KEGG pathways bubble plot of all DEGs was presented in [Fig. 3](#fig-3){ref-type="fig"}.

![The KEGG pathways bubble plot of DEGs.](peerj-07-7872-g003){#fig-3}
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###### Top 5 enriched pathways of the upregulated and downregulated DEGs.

![](peerj-07-7872-g009)

  Pathway ID   Name                                                        Count   *P*-value     Genes                                                                                                                                                                                     State
  ------------ ----------------------------------------------------------- ------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------
  hsa01100     Metabolic pathways                                          27      0.001161421   SAT1, NAMPT, SORD, GCNT2, GALNT7, GLUD1, PPT1, GGT1, ACSL1, ALDH1A3, ARG2, FASN, AMD1, ACSL3, DHCR24, UAP1, ACLY, ADI1, RDH11, FOLH1, ALOX15B, PLA2G7, PLA2G2A, ABAT, MBOAT2, SMS, DCXR   Upregulated
  hsa01212     Fatty acid metabolism                                       5       0.002342524   ACSL1, SCD, FASN, PPT1, ACSL3                                                                                                                                                             Upregulated
  hsa00330     Arginine and proline metabolism                             4       0.020729538   SAT1, ARG2, AMD1, SMS                                                                                                                                                                     Upregulated
  hsa03320     PPAR signaling pathway                                      4       0.043990087   ACSL1, SCD, DBI, ACSL3                                                                                                                                                                    Upregulated
  hsa00061     Fatty acid biosynthesis                                     3       0.009820063   ACSL1, FASN, ACSL3                                                                                                                                                                        Upregulated
  hsa04974     Protein digestion and absorption                            3       0.017282616   ATP1B1, ATP1A2, COL5A3                                                                                                                                                                    Downregulated
  hsa04960     Aldosterone-regulated sodium reabsorption                   2       0.087044909   ATP1B1, ATP1A2                                                                                                                                                                            Downregulated
  hsa04973     Carbohydrate digestion and absorption                       2       0.093437569   ATP1B1, ATP1A2                                                                                                                                                                            Downregulated
  hsa04978     Mineral absorption                                          2       0.097676003   ATP1B1, ATP1A2                                                                                                                                                                            Downregulated
  hsa04961     Endocrine and other factor-regulated calcium reabsorption   2       0.099788246   ATP1B1, ATP1A2                                                                                                                                                                            Downregulated

PPI network construction and modules analyses
---------------------------------------------

The STRING online database was applied to analyze the 252 identified DEGs and to construct a PPI network, which consisted of 181 nodes interacting with each other via 403 edges. The results were downloaded for further analysis by Cytoscape software. According to the descending order of degree value, the top five hub genes were subsequently screened, namely Kallikrein-related peptidase 3 (KLK3), CDH1, Kallikrein-related peptidase 2 (KLK2), forkhead box A1 (FOXA1), and EPCAM, as presented in [Table 4](#table-4){ref-type="table"}.
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###### Top five hub genes in the protein--protein interaction (PPI) network.

![](peerj-07-7872-g010)

  Gene symbol   Gene description                    Degree   Log~2~FC      *P*-Value
  ------------- ----------------------------------- -------- ------------- -------------
  KLK3          Kallikrein-related peptidase 3      26       2.019308668   2.04E-11
  CDH1          Cadherin 1                          22       1.21816524    5.18E-09
  KLK2          Kallikrein-related peptidase 2      21       1.954704556   5.64E-11
  FOXA1         Forkhead Box A1                     20       1.922009952   1.66E-11
  EPCAM         Epithelial cell adhesion molecule   19       1.076626501   0.000999371

Furthermore, seven functional cluster modules were filtered from the PPI network using the Molecular Complex Detection (MCODE) plugin of the Cytoscape software, and the top two modules ([Fig. 4](#fig-4){ref-type="fig"}) were selected for further KEGG pathway enrichment analyses using the DAVID database. As shown in [Table 5](#table-5){ref-type="table"}, the results indicated that the genes in Module 1 are mainly enriched in adherens junction and Hippo signaling pathway; while the genes in Module 2 are mainly enriched in FA metabolism, FA biosynthesis, PPAR signaling pathway, and FA degradation.

![Top two modules extracted from the PPI network.\
(A) Module 1. (B) Module 2. Circles represent genes, lines represent interactions between gene-encoded proteins and line colors represent evidence of interactions between proteins. PPI, protein--protein interaction.](peerj-07-7872-g004){#fig-4}
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###### Pathway enrichment analysis of the genes in the top two Modules.

![](peerj-07-7872-g011)

  Module     Pathway                   Count   *P*-value     Genes
  ---------- ------------------------- ------- ------------- -------------------------
  Module 1   Adherens junction         2       1.0E-2        CDH1, SNAI2
             Hippo signaling pathway   2       2.0E-2        CDH1, SNAI2
  Module 2   Fatty acid metabolism     4       1.97E-05      ACSL1, SCD, FASN, ACSL3
             Fatty acid biosynthesis   3       9.79E-05      ACSL1, FASN, ACSL3
             PPAR signaling pathway    3       0.002925067   ACSL1, SCD, ACSL3
             Fatty acid degradation    2       0.047850686   ACSL1, ACSL3

Validation of hub genes expression in multiple databases
--------------------------------------------------------

As shown in [Table 6](#table-6){ref-type="table"}, the literature search in Pubmed/GEO regarding gene expression profiles of PCa versus NP tissues yielded 10 relevant studies, five ([@ref-10]; [@ref-17]; [@ref-18]; [@ref-19]; [@ref-24]) of which were based on a single GEO dataset whereas the other five studies ([@ref-36]; [@ref-57]; [@ref-61]; [@ref-64]; [@ref-71]) were integrated bioinformatic analyses based on multiple GEO datasets. The hub genes reported by the 10 eligible studies were extracted and compared with those identified in the present study. As marked in bold fonts in [Table 6](#table-6){ref-type="table"}, there were some overlapped findings between our studies and other studies: our identified hub genes FOXA1, CDH1, and EPCAM were seen in two ([@ref-17]; [@ref-61]), one ([@ref-19]), and one ([@ref-36]) other studies, respectively.
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###### Comparisons between the present study and other studies using the GEO datasets.

![](peerj-07-7872-g012)

  Study               Dataset                                                                                                                                                                                                                  Sample size (PCa, NP)   Hub genes
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------- -------------------------------------------------------------------------
  [@ref-17].          --                                                                                                                                                                                                                       3, 1                    TSPAN1, BMPR1B, **FOXA1**, STEAP1, RCAN3, S100P, LYZ, SCGB3A1, IL8, DPT
  [@ref-10]           --                                                                                                                                                                                                                       4, 4                    PPFIA2, PTPRT, PTPRR, PRR16, CHRM2, KRT23, CYP3A4, CYP3A7, DPYS, DUOXA1
  [@ref-19]           [GSE26910](GSE26910)                                                                                                                                                                                                     6, 6                    **CDH1**, BMP2, NKX3-1, PPARG, PRKAR2B
  [@ref-71]           [GSE38241](GSE38241), [GSE3933](GSE3933)                                                                                                                                                                                 47, 37                  CDCA8, CDCA5, UBE2C, TK1
  [@ref-18]           [GSE55945](GSE55945)                                                                                                                                                                                                     18, 8                   RPS21, FOXO1, BIRC5, POLR2H, RPL22L1, NPM1
  [@ref-24]           [GSE46602](GSE46602)                                                                                                                                                                                                     36, 14                  PIK3R1, BIRC5, ITGB4, RRM2, TOP2A, ANXA1, LPAR1, ITGB8
  [@ref-36]           [GSE32448](GSE32448), [GSE45016](GSE45016), [GSE46602](GSE46602), [GSE104749](GSE104749)                                                                                                                                 90, 59                  **EPCAM**, TWIST1, CD38, VEGFA
  [@ref-57]           [GSE6919](GSE6919), [GSE6956](GSE6956), [GSE32448](GSE32448), [GSE32571](GSE32571), [GSE35988](GSE35988), [GSE46602](GSE46602), [GSE68555](GSE68555), [GSE69223](GSE69223), [GSE70768](GSE70768), [GSE88808](GSE88808)   569, 402                LMNB1, TK1, RACGAP1, ZWINT
  [@ref-61]           [GSE38240](GSE38240), [GSE26910](GSE26910)                                                                                                                                                                               14, 10                  IGF2, GATA5, F10, CFI, AGTR1, **FOXA1**, BZRAP1-AS1, KRT8
  [@ref-64]           [GSE26910](GSE26910), [GSE30174](GSE30174), [GSE46602](GSE46602), [GSE55945](GSE55945), [GSE69223](GSE69223)                                                                                                             140, 53                 IKZF1, PPM1A, FBP1, SMCHD1, ALPL, CASP5, PYHIN1, DAPK1, CASP8
  The present study   [GSE103512](GSE103512)                                                                                                                                                                                                   60, 7                   KLK3, **CDH1**, KLK2, **FOXA1**, **EPCAM**

**Note:**

Bold fonts represent overlapped hub genes among studies.

Next, we further validated our findings using data from TCGA. GEPIA was applied to determine the expression differences of hub genes between PCa and NP tissues. As shown in [Fig. 5A](#fig-5){ref-type="fig"}, mRNA levels of KLK3, CDH1, FOXA1, and EPCAM were significantly upregulated in PCa samples compared with NP samples; but there was no significant difference in the mRNA level of KLK2 between PCa and NP samples. Besides, we investigate the prognostic values of hub genes using TCGA data and conducted survival analyses with UCSC Xena online tools. As suggested in [Fig. 5B](#fig-5){ref-type="fig"}, all five hub genes had no statistically significant impact on PCa patients' OSs. Furthermore, we put the top 10 significantly upregulated and downregulated DEGs into survival analysis and found two genes had significant impact: the relative higher expression of ABCC4 (upregulated) as well as relative lower expression of SLPI (downregulated) were associated with poorer OS.

![Validation of hub genes using TCGA data.\
Relative expression of hub genes between PCa and NP samples in the GEPIA database (the threshold was set as \|log~2~FC\| = 1, *P* = 0.05, \**P* \< 0.05): (A) KLK3; (B) CDH1; (C) KLK2; (D) FOXA1; (E) EPCAM. The relationship of hub genes and top DEGs with the overall survival of TCGA PCa cohorts analyzed by the UCSC Xena online tools: (F) KLK3; (G) CDH1; (H) KLK2; (I) FOXA1; (J) EPCAM; (K) ABCC4; (L) SLPI. TCGA, The Cancer Genome Atlas; GEPIA, the Gene Expression Profiling Interactive Analysis database; UCSC, University of California Santa Cruz.](peerj-07-7872-g005){#fig-5}

Furthermore, an overview of hub genes expression in multiple types of cancers revealed that all five hub genes were remarkably overexpressed in PCa tissues compared with NP tissues according to the Oncomine database ([Fig. 6](#fig-6){ref-type="fig"}).

![An overview of mRNA levels of hub genes in various types of cancer based on Oncomine data.\
The numbers in colored grids shows the counts of datasets with statistically significant mRNA overexpression (red) or low expression (blue) of genes. Grid color was determined by the best gene rank percentile for analysis within the grids. The threshold was set as gene rank percentile = All, *P* = 0.05, and FC = 2.](peerj-07-7872-g006){#fig-6}

Discussion
==========

As one of the leading healthcare concerns worldwide, PCa has become one of the most prevalent malignancies of adult males with an incidence of around 0.01% ([@ref-27]). Although numerous progress has been made to uncover the molecular mechanisms of PCa development and progression, the outcomes remain obscure and the inconsistencies among different published studies are obvious ([@ref-5]). The main reason for such phenomenon is generally thought to be the complexity and heterogeneity nature of PCa as a whole ([@ref-32]; [@ref-63]). Thus, it's of vital significance to perform further research in this regard to validate and update the information acquired.

In the current study, we first screened a total of 252 (186 upregulated and 66 downregulated) DEGs from the unused GEO dataset [GSE103512](GSE103512). The GO/KEGG pathway enrichment analyses were implemented thereafter. Upregulated DEGs were mainly enriched in metabolic pathways, FA metabolism, and PPAR signaling pathway; whereas downregulated DEGs were mostly associated with protein digestion and absorption. Metabolism alteration is a hallmark of cancer. It is well demonstrated that the cancerous cellular metabolisms were urged to adapt themselves to the high proliferation rate and nutritional requirement so as to constantly support the increased cell division ([@ref-9]; [@ref-54]). For PCa, one of the most noticeable metabolic changes is, as our results indicated, the FA or lipid metabolism ([@ref-14]; [@ref-66]). The lipid biosynthesis is essential for membrane formation and cell signaling; for instance, the metabolic intermediates of de novo lipogenesis can serve as second messengers and regulate PCa migration and invasion ([@ref-20]). Moreover, the lipid metabolism of PCa is closely related to androgen by androgen receptor (AR) signaling. For examples, AR signaling can elevate the uptake of exogenous lipids by PCa cells ([@ref-34]) as well as stimulate adipose tissues to release FA ([@ref-46]). Furthermore, the PPARs family participate participates greatly in metabolic regulation. For example, PPARγ is a nuclear FA receptor which can interact with androgen receptor (AR) and regulate growth of PCa ([@ref-47]). The FA-binding protein 5 (FABP5)-PPARγ signaling pathway promotes the malignant progression of castration-resistant PCa cells ([@ref-28]; [@ref-29]). Recently, the FABP5 inhibitor dmrFABP5 were illustrated to inhibit the FABP5-PPARγ pathway to suppress the malignant progression of PCa cells ([@ref-1]). Therefore, targeting the above pathways might aid in developing effective strategy for the treatment of PCa.

Next, we constructed PPI networks with the DEGs and identified the following top five hub genes: KLK3, CDH1, KLK2, FOXA1, and EPCAM. All hub genes exhibited upregulated expressions in PCa compared to NP tissues. Both KLK3 and KLK2 belong to the Kallikrein-related peptidases (KLKs) family. Expressed and secreted by glandular epithelia of many organs including skin, mammary gland, prostate, colon, pancreas and brain, KLKs are a sort of serine proteases existed in the body fluids excreted by the above organs such as sweat, milk, and seminal fluid, involving in various physiological functions like electrolyte balance, extracellular matrix remodeling, and prohormone processing ([@ref-7]; [@ref-55]). Aberrant expression of KLKs can be found in several kinds of malignancies including ovarian cancer ([@ref-35]), breast cancer ([@ref-21]), gastrointestinal cancer ([@ref-31]), and PCa ([@ref-39]; [@ref-41]). Further on, it was suggested that KLKs could lead to proliferation of the epithelium via protease-activated receptors, which might contribute to PCa development ([@ref-50]). Several studies have highlighted the association between KLK3 gene polymorphism and susceptibility to PCa ([@ref-11]; [@ref-16]; [@ref-44]), and [@ref-68] successfully combined the KLK3 genetics analysis and free-to-total PSA ratio for PCa diagnosis. Similarly, KLK2 was reported to be potential marker for diagnosis because its polymorphism can increase vulnerability to PCa ([@ref-13]; [@ref-45]). And more notably, the loss of miR-378 (a regulator of KLK2) in PCa was found to be correlated with aggressive phenotype and short-term relapse events ([@ref-3]). Both KLK2 and KLK3 were reported to elevate the level of insulin-like growth factor (IGF) by cleaving the IGF-binding proteins, which consequently affects cell survival, mitogenesis, and differentiation. Analogously, KLK3 can cleave the TGFβ-binding proteins and activate TGFβ, resulting in cell proliferation ([@ref-7]).

The encoding product of CDH1 gene, namely E-cadherin, participates in cell-cell adhesion and the maintenance of cell differentiation as well as normal structure of epithelium ([@ref-40]; [@ref-60]). Pathologically, inactivation or absence of CDH1 expression can decrease intercellular junctions and thus promote cancer invasion and metastasis, as seen in diffuse gastric cancer ([@ref-43]) and lobular breast cancer ([@ref-42]). Contrary to expectation, our results indicated that CDH1 expression turned out to be significantly upregulated in PCa compared to NP tissues. Consistent with our results, another study using the [GSE26910](GSE26910) dataset also found overexpressed CDH1 in PCa samples ([@ref-19]). It was hypothesized that overexpression of CDH1 might have an impact on oncogenesis since previous research has indicated the intercellular adhesion between cancer and normal cells were enhanced in the late stage of tumor formation ([@ref-2]). Plus, polymorphism of CDH1 was also found to elevate the risk of PCa ([@ref-25]; [@ref-49]). Future work is merited to explore the expression changes of CDH1 in different stages of PCa.

Forkhead Box A1, also known as hepatocyte nuclear factor 3α, is a transcription factor that plays important roles in development as well as cancer formation ([@ref-6]). FOXA1 has multiple impact on PCa, including (1) controls the morphogenesis and cell differentiation of prostate ([@ref-23]); (2) facilitates AR transactivation which is essential for PCa proliferation and survival ([@ref-70]); (3) inhibits PCa progress towards neuroendocrine prostate cancer, whose prognosis is worse ([@ref-30]); (4) downregulates TGF-β signaling and thus suppresses castration-resistant prostate cancer progression ([@ref-58]). Our findings were validated by another expression profiling study ([@ref-17]), and the complexity of functions of FOXA1 still calls for further research to fully interpret its role in PCa development and progression.

Epithelial cell adhesion molecule encodes epithelial cell adhesion molecule, also known as CD326, is usually high expressed in cancer tissues and participates in intercellular adhesion limitation, cell signaling, migration, proliferation, and differentiation ([@ref-37]). Consistent with our results, EPCAM is shown to be overexpressed in localized and metastatic PCa ([@ref-38]). Other integrated bioinformatic analysis using four GEO datasets also validated our findings ([@ref-36]).

When it comes to validation of the identified hub genes, three of them (CDH1, FOXA1, and EPCAM) were validated by other studies using relevant GEO datasets; four genes (except KLK2) were validated by TCGA data; and all five genes were validated by the Oncomine data. This implied their potentials as effective and reliable biomarkers for diagnosis and as possible therapeutic targets. However, in survival analysis using TCGA cohorts, all hub genes turned out to have insignificant impact on PCa patients' OS. To add readability, we put the top 10 upregulated and downregulated DEGs into the survival analysis, outputting two significant genes, namely ABCC4 and SLPI. ABCC4 (ATP-cassette binding protein 4), which was significantly upregulated as our results revealed, its relatively higher expression was associated with poorer OS of PCa patients. This negative effect of ABCC4 expression toward PCa might result from that ABCC4 could decrease the efficacy of docetaxel in treating PCa cells ([@ref-48]). Conversely, the relatively higher level of downregulated DEG SLPI (Stomatin-like protein 1) was related to better OS of PCa patients. There are not many studies focused on SLPI. Intriguingly, it is revealed that overexpression of SLPI stabilizes F-box protein Fbw7-γ by inhibiting its degradation, which is implicated in the degradation of oncogene c-Myc ([@ref-69]). So SLPI might impact negatively on cell proliferation of PCa through the above mechanism. Therefore, these two genes might hopefully serve as prognostic indicators for PCa patients.

We also conducted a module analysis on the existing PPI network and selected the top two significant modules for the ensuing KEGG pathway enrichment analysis of the genes contained. The results demonstrated that the genes in Module 1 are mainly enriched in adherens junction and Hippo signaling pathway; while the genes in Module 2 are mainly enriched in FA metabolism, fatty acid biosynthesis, PPAR signaling pathway, and FA degradation. Apparently, the modules KEGG analyses were quite conformed to the overall KEGG results. The FA metabolism related pathways, PPAR signaling pathway, and cell adhesion-related hub genes and pathways were already discussed above. It was demonstrated that the activation of Hippo signaling pathway regulates cell growth and proliferation by inhibiting YAP and TAZ transcription co-activators, and its dysregulation impacts significantly on development of cancers including colon, liver, breast, lung, ovary, and prostate ([@ref-53]; [@ref-67]).

Conclusions
===========

By bioinformatic analyses including GO/KEGG enrichment, PPI network, hub gene identification, and module analysis, the current study validated KLK3, CDHI, FOXA1, and EPCAM might potentially serve as effective and reliable molecular biomarkers for diagnosis of PCa; and ABCC4 and SLPI might be utilized as prognostic indicators of PCa. However, further basic and clinical researches are necessary for the verification of the clinical value of our findings.
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